Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Approvable letter for Yaz

Jan. 26, 2006

MP-4 safe, reduces hypotensive episodes in orthopedic surgery patients

Jan. 25, 2006

Phase IIb study of obesity drug AOD-9604 proceeds on schedule

Jan. 25, 2006

FDA Advisory Committee recommends OTC approval of orlistat 60 mg

Jan. 25, 2006

ATL-962 for obesity and related disease begins phase II in Japan

Jan. 24, 2006

Takeda's SYR-322 begins phase III for diabetes

Jan. 24, 2006

Phase I study completed for KB-2115

Jan. 23, 2006

Merck Frosst presents a new potent, selective orally active cathepsin K inhibitor

Jan. 23, 2006

Recent patents describe novel agents for metabolic disorders

Jan. 20, 2006

Novel agents for diabetes reported in recent patent literature

Jan. 20, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...